Our previous study suggested that serum tumor markers (STMs) integrated with other clinical factors could be a valuable noninvasive tool for predicting EGFR mutations and ALK positivity in NSCLC patients [18]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.